DIVISLAB vs LUPIN
Side-by-side comparison of Divi's Laboratories Ltd. and Lupin Ltd.. Descriptive only — not investment advice.
Divi's Laboratories Ltd.
Pharma
Quality Score: 63/100
Lupin Ltd.
Pharma
Quality Score: 73/100
At a glance
| Metric | DIVISLAB | LUPIN |
|---|---|---|
| Quality Score | 63/100 | 73/100 |
| P/E (trailing) | 88.3 | 20.7 |
| Forward P/E | 57.1 | 23.6 |
| ROE | — | +26.9% |
| Profit margin | +26.1% | +19.1% |
| Debt-to-equity | 0.04 | 29.39 |
| Dividend yield | +0.36% | +0.74% |
| 1Y price return | +30.0% | +24.4% |
| From 52w high | -3.3% | -4.1% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.72 | 2.49 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
DIVISLAB trades at Rs 8,300, up 30.04% over the past year and 20.41% over the past 3 months, sitting 3.32% below its 52-week high with RSI at 73.92 (overbought). Q1FY27 results showed a 65.5% PAT surge on 28% revenue growth, drawing 6 positive items among the 8 news headlines tracked in early August 2026. The trailing PE of 88.34 is the highest among 6 tracked Pharma peers, against a mean analyst rating of 2.72 across 29 analysts (1-5 scale, lower = more constructive).
Lupin trades at a trailing PE of 20.74 (forward PE 23.59) with a trailing ROE of 26.91% and a quality score of 72, ranking 1st of 6 tracked pharma peers on PE, ROE, and quality score. Recent company-specific news is mixed: an FDA approval and a favorable plant inspection outcome sit alongside a product recall, against a backdrop of broader US generic-drug tariff coverage affecting the sector.
Pros
- ✓Q1FY27 PAT surged 65.5% YoY on 28% revenue growth, per results covered across NDTV Profit, scanx.trade, and Yahoo Finance between Aug 1-6, 2026.
- ✓5-year revenue growth of 27.8% and 5-year earnings growth of 65.7% outpace several sector peers.
- ✓Free cash flow was positive in 4 of the years tracked, and the price trades above both the 50-day (Rs 7,083.51) and 200-day (Rs 6,537.86) moving averages.
- ✓News flow over the tracked period is entirely non-negative (6 positive, 2 neutral, 0 negative of 8 headlines), including senior management appointments effective August 1, 2026.
- ✓Trailing ROE of 26.91% and quality score of 72 rank 1st of 6 tracked pharma peers, alongside a PE of 20.74 that is also the lowest in the peer set
- ✓5-year revenue growth of 31.9% and 5-year earnings growth of 89%
- ✓Free cash flow was positive in 4 of the years covered by the persistence dataset
- ✓Recent regulatory positives include US FDA approval and launch of a Sugammadex injection (Express Pharma, 2026-07-31) and a USFDA Establishment Inspection Report for the New Jersey plant with VAI classification (Medical Dialogues, 2026-07-03)
Cons
- ✗Trailing PE of 88.34 (forward 57.06) is the highest among the 6 Pharma peers tracked, ranking last (6th of 6) on that metric.
- ✗ROE has exceeded 15% in only 1 of the years tracked, with a consistency score of 50/100, and the debt trend is flagged 'rising' even though the absolute debt-to-equity ratio remains near zero.
- ✗RSI of 73.92 indicates overbought conditions, and the nearest identified support level (Rs 6,503.68) is 21.6% below the current price of Rs 8,300, a wide gap versus the single resistance level identified at Rs 8,585.
- ✗1-year price-change and some ROE data are missing for most of the 5 tracked Pharma peers, limiting how much of the sector ranking can be verified beyond PE and quality score.
- ✗Debt-to-equity trend is rising per the persistence data, even though the absolute level of roughly 0.29x remains low
- ✗ROE has been above 15% in only 2 of the years on record despite a current trailing ROE of 26.91%, with a consistency score of 69/100
- ✗A recall of more than 2.5 million prescription eye-drop bottles was reported over possible contamination (Fierce Pharma, 2026-07-13)
- ✗The quoted current price and moving averages do not carry an independent freshness timestamp for this run and news flow extends further into 2026 than the technical data appears to reflect
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.